MIRM News and Press, Mirum Pharmaceuticals Inc. From 01/31/24

2024-01-31 12:12:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-01-16 08:47:27 ET More on Mirum Pharmaceuticals Mirum Pharmaceuticals: Market Overreacts To Livmarli's Phase 2 Miss Mirum stock tumbles 20% premarket on failed drug study For further details see: Mirum Pharmaceuticals appoints Quan as its chief medical officer

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), today announced the appointment of Joanne Quan, MD as Chief Medical Officer. Dr. Quan will lead the global clinical development, clinical operations, and safety programs for Mirum’s pipeline of programs addressing rare diseases. Dr. Quan was ...

2024-01-11 12:30:02 ET Raymond James analyst issues MARKET OUTPERFORM recommendation for MIRM on January 11, 2024 01:00PM ET. The previous analyst recommendation was Market Outperform. MIRM was trading at $26.4 at issue of the analyst recommendation. The overall analyst ...

- $186-188 million in total revenue and $178-180 million net product sales expected for 2023, preliminary and unaudited - LIVMARLI net products sales of $141-143 million expected for 2023, representing approximately 89% year-over-year growth, preliminary and unaudited Mirum Pharmaceut...

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the identification, acquisition, development and commercialization of novel therapies for debilitating rare and orphan diseases, today announced that it will present at the 42 nd Annual J.P. Morgan Healthcare C...

2023-12-19 12:45:02 ET JMP Securities analyst issues UNDERPERFORM recommendation for MIRM on December 19, 2023 01:00PM ET. The previous analyst recommendation was Underperform. MIRM was trading at $31.41 at issue of the analyst recommendation. The overall analyst consens...

2023-12-19 09:10:24 ET Summary Mirum Pharmaceuticals, Inc. stock dropped 16% after its lead asset, Livmarli, failed to meet primary or secondary endpoints in a phase 2 trial for biliary atresia. This looks like an overreaction considering the small addressable market and no negati...

2023-12-19 07:30:02 ET Raymond James analyst issues STRONG BUY recommendation for MIRM on December 19, 2023 07:30AM ET. The previous analyst recommendation was Strong Buy. MIRM was trading at $29.385 at issue of the analyst recommendation. The overall analyst consensus :...

2023-12-18 11:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...